PDCD1 and cancer: Immunotherapy has opened a new era in cancer treatment with the FDA approval of several immune checkpoint inhibitors (ICI) which block checkpoint proteins from binding with their partner proteins (e.g. PD-1, PD-L1, CTLA-4, LAG-3) in tumors (13, 14).